5-HT1A receptor agonists are drugs that activate the 5-HT1A receptor, used in treating conditions like anxiety, depression, and schizophrenia.

Zealand Pharma has officially presented a request for drug approval to the United States' FDA for their medication glepaglutide, aiming to treat individuals with short bowel syndrome.

The U.S. FDA offers Fast Track Designation and Breakthrough Therapy Designation to speed up the development and review of drugs for serious conditions lacking treatments. Yet, they differ in key aspects.

Senti Bio has received the green light from the FDA for SENTI-202, aimed at addressing recurring or stubborn blood cancers, such as Acute Myeloid Leukemia.

MR(Mineralocorticoid Receptor) antagonists are drugs that block the mineralocorticoid receptor, aiding in the treatment of hypertension and heart failure.

Tyra Biosciences successfully administered the inaugural dose of TYRA-200 to a patient and shared encouraging progress on their TYRA-300 development.

Protein palmitoylation is a post-translational modification that involves the addition of a 16-carbon saturated fatty acid, typically palmitate (C16:0), to cysteine residues within target proteins.

U.S. health authorities expedite assessment of Patritumab Deruxtecan for select cases of advanced or widespread EGFR-altered Non-Small Cell Lung Cancer after first treatments.

Histamine receptor antagonists are drugs that block histamine action, relieving allergic reactions.

Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. have announced obtaining approval from Japan's Ministry of Health, Labour and Welfare to commercially distribute Rituxan®.

Ubiquitination is a process that involves adding a protein called ubiquitin to a substrate protein.

Mineralys Therapeutics Reports Initial Participant Receives Dose in Start-HTN, Their Second Major Study of Lorundrostat Aimed at Hypertension Management.